Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), an late-stage biotechnology company and leader in the discovery and development of novel therapies for the treatment of fibrotic diseases, today announced four presentations at the European Respiratory Society (ERS) International Congress 2024, taking place in Vienna, Austria, September 7-11, 2024.

Late Breaker – Oral and ePoster Presentations
Title: Evaluation of the antifibrotic activity of bexotegrast, a dual αVβ6/αVβ1 integrin inhibitor, in precision-cut lung slices prepared from non-IPF interstitial lung disease explants
Summary: OA951
Presenter: Martin Decaris, Ph.D., Pliant Therapeutics
Date: Sunday, September 8, 2024
Session: Sarcoidosis: new insights in disease epidemiology, immunology and treatment
Session time: 9:30 – 10:45 CEST